Cargando…

The Role of Mitochondrial DNA Damage and Repair in the Resistance of BCR/ABL-Expressing Cells to Tyrosine Kinase Inhibitors

Chronic myeloid leukemia (CML) is a hematological malignancy that arises from the transformation of stem hematopoietic cells by the fusion oncogene BCR/ABL and subsequent clonal expansion of BCR/ABL-positive progenitor leukemic cells. The BCR/ABL protein displays a constitutively increased tyrosine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glowacki, Sylwester, Synowiec, Ewelina, Blasiak, Janusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759915/ https://www.ncbi.nlm.nih.gov/pubmed/23965958 http://dx.doi.org/10.3390/ijms140816348

Ejemplares similares

UV Differentially Induces Oxidative Stress, DNA Damage and Apoptosis in BCR-ABL1-Positive Cells Sensitive and Resistant to Imatinib
por: Synowiec, Ewelina, et al.
Publicado: (2015)

Reactive Oxygen Species and Mitochondrial DNA Damage and Repair in BCR-ABL1 Cells Resistant to Imatinib
por: Blasiak, Janusz, et al.
Publicado: (2015)

Mitochondrial and Nuclear DNA Damage and Repair in Age-Related Macular Degeneration
por: Blasiak, Janusz, et al.
Publicado: (2013)

Doxorubicin Differentially Induces Apoptosis, Expression of Mitochondrial Apoptosis-Related Genes, and Mitochondrial Potential in BCR-ABL1-Expressing Cells Sensitive and Resistant to Imatinib
por: Synowiec, Ewelina, et al.
Publicado: (2015)

Bcr-Abl tyrosine kinase inhibitors- current status
por: Mughal, Anum, et al.
Publicado: (2013)

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
por: Carofiglio, Francesca, et al.
Publicado: (2020)

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
por: Cuellar, Sandra, et al.
Publicado: (2017)

Combination of Bortezomib and Mitotic Inhibitors Down-Modulate Bcr-Abl and Efficiently Eliminates Tyrosine-Kinase Inhibitor Sensitive and Resistant Bcr-Abl-Positive Leukemic Cells
por: Bucur, Octavian, et al.
Publicado: (2013)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
por: Takeuchi, Asako, et al.
Publicado: (2020)

Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
por: de Almeida, Maria Helena, et al.
Publicado: (2014)

BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
por: Haguet, Hélène, et al.
Publicado: (2018)

BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon
por: Stanchina, Michele, et al.
Publicado: (2020)

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
por: Kauer, Joseph, et al.
Publicado: (2022)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

NS-187 (INNO-406), a Bcr-Abl/Lyn Dual Tyrosine Kinase Inhibitor
por: Niwa, Tomoko, et al.
Publicado: (2007)

Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors
por: Wang, Yihua, et al.
Publicado: (2023)

Genetic Variability in DNA Repair Proteins in Age-Related Macular Degeneration
por: Blasiak, Janusz, et al.
Publicado: (2012)

Tyrosine kinase inhibitors induce alternative spliced BCR‐ABL (Ins35bp) variant via inhibition of RNA polymerase II on genomic BCR‐ABL
por: Yuda, Junichiro, et al.
Publicado: (2020)

Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines
por: Lu, Liu, et al.
Publicado: (2018)

Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells
por: Tsubaki, Masanobu, et al.
Publicado: (2017)

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
por: Trela, Ewelina, et al.
Publicado: (2014)

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
por: Mesa, Ruben A
Publicado: (2007)

BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
por: Terasawa, Teruhiko, et al.
Publicado: (2011)

Adverse Reaction Profiles Related to Gastrointestinal Bleeding Events Associated with BCR-ABL Tyrosine Kinase Inhibitors
por: Kawada, Kei, et al.
Publicado: (2022)

Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and -resistant BCR-ABL-dependent chronic myeloid leukemia
por: Singh, Neetu, et al.
Publicado: (2018)

A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
por: Wagle, M, et al.
Publicado: (2016)

Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review
por: Al Hamad, Mohammad
Publicado: (2022)

β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
por: Eiring, Anna M., et al.
Publicado: (2015)

Modeling the influence of stromal microenvironment in the selection of ENU-induced BCR-ABL1 mutants by tyrosine kinase inhibitors
por: Aggoune, Djamel, et al.
Publicado: (2014)

Evolution of BCR/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase Inhibitor
por: Vaidya, Shantashri, et al.
Publicado: (2015)

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
por: Etienne, Gabriel, et al.
Publicado: (2019)

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
por: Pennisi, Maria Stella, et al.
Publicado: (2019)

Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance
por: Aghel, Nazanin, et al.
Publicado: (2017)

Association of Bcr-Abl Tyrosine Kinase Inhibitors With Hepatitis B Virus Reactivation Requiring Antiviral Treatment in Taiwan
por: Wang, Ling-Yi, et al.
Publicado: (2021)

The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach
por: Huang, Ting-Ting, et al.
Publicado: (2021)

Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase
por: Reckel, Sina, et al.
Publicado: (2017)

Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity
por: Yu, Brian, et al.
Publicado: (2022)

Monoubiquitinated Fanconi Anemia D2 (FANCD2-Ub) Is Required for BCR-ABL1 Kinase -Induced Leukemogenesis
por: Koptyra, Mateusz, et al.
Publicado: (2011)

Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells
por: Tsubaki, Masanobu, et al.
Publicado: (2023)

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
por: Okabe, Seiichi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1nrhhuvnnhhv3o67j7j53ue5i6